Abstract
Pulmonary tuberculosis infections caused by multi-drug resistant Mycobacterium tuberculosis has progressed to extensively drug resistant status (XDR-TB). XDR-TB is very difficult to treat successfully and results in high mortality. Globally, XDR-TB is now a major threat, especially to India and countries that were once part of the Soviet Union.
There is a potential alternative to current ineffective therapy that is solidly supported by in vitro, ex vivo and in vivo studies. It has reported successful therapies in 10 out of 12 non-responsive XDR-TB patients. That therapy is thioridazine, and it is the purpose of this mini-review to provide the rationale for thioridazine therapy, especially for compassionate reasons, when all other therapies have failed, depicting on extremely poor prognosis.
Keywords: Macrophage activation, MDR-TB, Phenothiazines, Therapy, Thioridazine, XDR-TB, Pulmonary tuberculosis infections, Mycobacterium tuberculosis, thioridazine therapy, mycobacteria bind, pneumocyte II, isoniazid, rifampicin, kanamycin, amikacin, capreomycin, psychosis, syphilis, narcotize, colorless neuroleptic chlorpromazine, neuroleptic thioridazine
Letters in Drug Design & Discovery
Title: Thioridazine: Alternative and Potentially Effective Therapy of the XDRTB Patient
Volume: 8 Issue: 2
Author(s): Leonard Amaral, Marta Martins and Miguel Viveiros
Affiliation:
Keywords: Macrophage activation, MDR-TB, Phenothiazines, Therapy, Thioridazine, XDR-TB, Pulmonary tuberculosis infections, Mycobacterium tuberculosis, thioridazine therapy, mycobacteria bind, pneumocyte II, isoniazid, rifampicin, kanamycin, amikacin, capreomycin, psychosis, syphilis, narcotize, colorless neuroleptic chlorpromazine, neuroleptic thioridazine
Abstract: Pulmonary tuberculosis infections caused by multi-drug resistant Mycobacterium tuberculosis has progressed to extensively drug resistant status (XDR-TB). XDR-TB is very difficult to treat successfully and results in high mortality. Globally, XDR-TB is now a major threat, especially to India and countries that were once part of the Soviet Union.
There is a potential alternative to current ineffective therapy that is solidly supported by in vitro, ex vivo and in vivo studies. It has reported successful therapies in 10 out of 12 non-responsive XDR-TB patients. That therapy is thioridazine, and it is the purpose of this mini-review to provide the rationale for thioridazine therapy, especially for compassionate reasons, when all other therapies have failed, depicting on extremely poor prognosis.
Export Options
About this article
Cite this article as:
Amaral Leonard, Martins Marta and Viveiros Miguel, Thioridazine: Alternative and Potentially Effective Therapy of the XDRTB Patient, Letters in Drug Design & Discovery 2011; 8 (2) . https://dx.doi.org/10.2174/157018011794183860
DOI https://dx.doi.org/10.2174/157018011794183860 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Approaches to Drug-DNA Interactions Based on Graphical Representation and Numerical Characterization of DNA Sequences
Current Computer-Aided Drug Design Aspartame Induce Modification in Membrane Bound and Antioxidant Enzymes in Liver and Kidney of Wistar Albino Rats
Current Nutrition & Food Science Artemisia Species as Potential Weapon Against Agents and Agricultural Pests
Current Biotechnology Tumor Necrosis Factor Inhibitors as Therapeutic Choice in Psoriasis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Orchestration of Host-Pathogen Interaction: Relevance of Iron in Generation of Potent Anti-M. tuberculosis Immunity
Current Pharmaceutical Biotechnology Newer Insights in Personalized and Evidence Based Medicine- the Role of MicroRNAs
Current Pharmacogenomics and Personalized Medicine Recent Developments in Protein and Cell-Targeted Aptamer Selection and Applications
Current Medicinal Chemistry Subject Index To Volume 3
Current Drug Delivery Recent Development of Coumarin Derivatives as Potential Antiplasmodial and Antimalarial Agents
Current Topics in Medicinal Chemistry Formulation of Rifampicin Loaded PEGylated 5.0G EDA-PAMAM Dendrimers as Effective Long-Duration Release Drug Carriers
Current Drug Therapy Chemistry and Biology of Indoles and Indazoles: A Mini-Review
Mini-Reviews in Medicinal Chemistry Ethnic Differences in Pharmacogenetically Relevant Genes
Current Drug Targets Vaccines and Vaccine Strategies Against HIV
Current Drug Targets Anti-Inflammatory Activity of Polysaccharide Fraction of Curcuma longa Extract (NR-INF-02)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Short-Term Transfer of Knowledge Assessment in the Military International HIV Training Program (MIHTP)
Current HIV Research A Review on the Phytochemicals, Ethnomedicine Uses and Pharmacology of Ficus Species
Current Traditional Medicine Allergic Bronchopulmonary Aspergillosis: AllA Radiologist Needs To Know
Current Pediatric Reviews Nanoparticulate Drug Delivery System to Overcome the Limitations of Conventional Curcumin in the Treatment of Various Cancers: A Review
Drug Delivery Letters The Impact of the Salting-Out Technique on the Preparation of Colloidal Particulate Systems for Pharmaceutical Applications
Recent Patents on Drug Delivery & Formulation Inhalation Delivery of Host Defense Peptides (HDP) using Nano- Formulation Strategies: A Pragmatic Approach for Therapy of Pulmonary Ailments
Current Protein & Peptide Science